Chugai Pharmaceutical Co Stock Net Income
| CHGCF Stock | USD 59.73 0.06 0.10% |
As of the 16th of February 2026, Chugai Pharmaceutical shows the Risk Adjusted Performance of 0.0969, mean deviation of 2.86, and Downside Deviation of 3.9. Chugai Pharmaceutical technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Chugai Pharmaceutical treynor ratio, as well as the relationship between the potential upside and expected short fall to decide if Chugai Pharmaceutical is priced correctly, providing market reflects its regular price of 59.73 per share. Given that Chugai Pharmaceutical has jensen alpha of 0.3998, we suggest you to validate Chugai Pharmaceutical Co's prevailing market performance to make sure the company can sustain itself at a future point.
Chugai Pharmaceutical's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Chugai Pharmaceutical's valuation are provided below:Chugai Pharmaceutical Co does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Chugai |
Chugai Pharmaceutical 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Chugai Pharmaceutical's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Chugai Pharmaceutical.
| 11/18/2025 |
| 02/16/2026 |
If you would invest 0.00 in Chugai Pharmaceutical on November 18, 2025 and sell it all today you would earn a total of 0.00 from holding Chugai Pharmaceutical Co or generate 0.0% return on investment in Chugai Pharmaceutical over 90 days. Chugai Pharmaceutical is related to or competes with GSK Plc, Daiichi Sankyo, Daiichi Sankyo, Siemens Healthineers, MERCK Kommanditgesells, Merck KGaA, and Sartorius Aktiengesellscha. Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sa... More
Chugai Pharmaceutical Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Chugai Pharmaceutical's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Chugai Pharmaceutical Co upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.9 | |||
| Information Ratio | 0.0916 | |||
| Maximum Drawdown | 18.16 | |||
| Value At Risk | (4.75) | |||
| Potential Upside | 7.0 |
Chugai Pharmaceutical Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Chugai Pharmaceutical's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Chugai Pharmaceutical's standard deviation. In reality, there are many statistical measures that can use Chugai Pharmaceutical historical prices to predict the future Chugai Pharmaceutical's volatility.| Risk Adjusted Performance | 0.0969 | |||
| Jensen Alpha | 0.3998 | |||
| Total Risk Alpha | 0.1249 | |||
| Sortino Ratio | 0.0878 | |||
| Treynor Ratio | 8.35 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Chugai Pharmaceutical's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Chugai Pharmaceutical February 16, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0969 | |||
| Market Risk Adjusted Performance | 8.36 | |||
| Mean Deviation | 2.86 | |||
| Semi Deviation | 3.45 | |||
| Downside Deviation | 3.9 | |||
| Coefficient Of Variation | 906.31 | |||
| Standard Deviation | 3.74 | |||
| Variance | 13.99 | |||
| Information Ratio | 0.0916 | |||
| Jensen Alpha | 0.3998 | |||
| Total Risk Alpha | 0.1249 | |||
| Sortino Ratio | 0.0878 | |||
| Treynor Ratio | 8.35 | |||
| Maximum Drawdown | 18.16 | |||
| Value At Risk | (4.75) | |||
| Potential Upside | 7.0 | |||
| Downside Variance | 15.24 | |||
| Semi Variance | 11.87 | |||
| Expected Short fall | (3.02) | |||
| Skewness | (0.04) | |||
| Kurtosis | 0.2996 |
Chugai Pharmaceutical Backtested Returns
Chugai Pharmaceutical appears to be very steady, given 3 months investment horizon. Chugai Pharmaceutical secures Sharpe Ratio (or Efficiency) of 0.0684, which signifies that the company had a 0.0684 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Chugai Pharmaceutical Co, which you can use to evaluate the volatility of the firm. Please makes use of Chugai Pharmaceutical's Downside Deviation of 3.9, mean deviation of 2.86, and Risk Adjusted Performance of 0.0969 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Chugai Pharmaceutical holds a performance score of 5. The firm shows a Beta (market volatility) of 0.0482, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Chugai Pharmaceutical's returns are expected to increase less than the market. However, during the bear market, the loss of holding Chugai Pharmaceutical is expected to be smaller as well. Please check Chugai Pharmaceutical's expected short fall, day median price, and the relationship between the potential upside and accumulation distribution , to make a quick decision on whether Chugai Pharmaceutical's price patterns will revert.
Auto-correlation | 0.10 |
Insignificant predictability
Chugai Pharmaceutical Co has insignificant predictability. Overlapping area represents the amount of predictability between Chugai Pharmaceutical time series from 18th of November 2025 to 2nd of January 2026 and 2nd of January 2026 to 16th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Chugai Pharmaceutical price movement. The serial correlation of 0.1 indicates that less than 10.0% of current Chugai Pharmaceutical price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.1 | |
| Spearman Rank Test | -0.04 | |
| Residual Average | 0.0 | |
| Price Variance | 7.92 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Chugai Pharmaceutical Co reported net income of 303 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The net income for all United States stocks is significantly lower than that of the firm.
Chugai Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Chugai Pharmaceutical's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Chugai Pharmaceutical could also be used in its relative valuation, which is a method of valuing Chugai Pharmaceutical by comparing valuation metrics of similar companies.Chugai Pharmaceutical is currently under evaluation in net income category among its peers.
Chugai Fundamentals
| Return On Equity | 0.29 | |||
| Return On Asset | 0.2 | |||
| Profit Margin | 0.30 % | |||
| Operating Margin | 0.42 % | |||
| Current Valuation | 39.67 B | |||
| Shares Outstanding | 1.64 B | |||
| Shares Owned By Insiders | 59.99 % | |||
| Shares Owned By Institutions | 18.71 % | |||
| Price To Earning | 19.49 X | |||
| Price To Book | 3.95 X | |||
| Price To Sales | 0.04 X | |||
| Revenue | 999.76 B | |||
| Gross Profit | 783.7 B | |||
| EBITDA | 419.43 B | |||
| Net Income | 303 B | |||
| Cash And Equivalents | 545.3 B | |||
| Cash Per Share | 331.48 X | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 3.21 X | |||
| Book Value Per Share | 865.88 X | |||
| Cash Flow From Operations | 279.63 B | |||
| Earnings Per Share | 1.71 X | |||
| Price To Earnings To Growth | 14.84 X | |||
| Number Of Employees | 43 | |||
| Beta | 0.52 | |||
| Market Capitalization | 44.99 B | |||
| Total Asset | 1.54 T | |||
| Retained Earnings | 500.19 B | |||
| Working Capital | 435.19 B | |||
| Current Asset | 542.89 B | |||
| Current Liabilities | 107.7 B | |||
| Annual Yield | 0.02 % | |||
| Net Asset | 1.54 T | |||
| Last Dividend Paid | 78.0 |
About Chugai Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Chugai Pharmaceutical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Chugai Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Chugai Pharmaceutical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Chugai Pink Sheet
Chugai Pharmaceutical financial ratios help investors to determine whether Chugai Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Chugai with respect to the benefits of owning Chugai Pharmaceutical security.